Results of a new study conducted by the Chronic Disease Research Group show daily home hemodialysis patients have a 16% lower risk of death, 8% lower risk of hospitalization, and 38% lower risk of therapy attrition than peritoneal dialysis patients
It’s been about four years since NxStage submitted the System One cycler to the FDA to try to get a new indication for nocturnal home use. Four years. An entire Presidency’s worth of delays, additional studies, conference calls—and more delays.
Fresenius has agreed to help Baxter meet customer needs as the North American chapter of the International Society of Peritoneal Dialysis expresses concern to the FDA over Baxter's continuing PD fluid shortage